Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q3 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mail
Get Alerts AMLX Hot Sheet
Join SI Premium – FREE
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of ($1.07), $0.37 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $416 thousand.
For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lear Corp. (LEA) Tops Q3 EPS by 39c ; Offers Guidance
- Rosenblatt Reiterates Neutral Rating on Pinterest Inc (PINS)
- Sirius XM Radio (SIRI) PT Raised to $47 at Rosenblatt
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
